Yeah Koo & Fuzz ... past study "shortcomings" hurt, lots of promise, but not nearer the finish line, yet. Unless/until you consider the amount of gained knowledge and refinements toward the "next" study. The world, including RVX science, is still trying to more accurately define and understand apabetalone, how it works, and how it is to be applied.

The BTD plus BoM2 design seems to imply that both RVX and the FDA are coming closer and honing in on the benefits and path to registration.

We do have some remarkable milestones with BTD, and safety. Just need more derisking and proof we are actually likely to reach registration and commercialization so that an investor ROI looks attainable and attractive imho.

Based on what I've seen/heard so far, I do have a high-er degree of confidence that BoM2 can/will be a success finally, based on the study enrollement targets profile and given past post hoc data and p values for specific profiles (sick patients, SGLT2, stroke removed). Just dismayed to have to wait for it again tick tock.

Maybe some positive Covid news soon will give us a bounce, and some momentum heading into BoM2?

Anyone know the % of "BTD" drugs/companies that make it to actual registration? I would assume it is a pretty high percentage, but google didn't help with likelood of approval for BTD's?